Christine Leong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7197275/publications.pdf

Version: 2024-02-01

687220 677027 34 518 13 22 citations h-index g-index papers 34 34 34 829 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research. Drugs in R and D, 2017, 17, 493-507.	1.1	181
2	Antidepressants for Depression in Patients with Dementia: A Review of the Literature. The Consultant Pharmacist, 2014, 29, 254-263.	0.4	45
3	Psychotropic Drug Use before, during, and after Pregnancy: A Population-Based Study in a Canadian Cohort (2001-2013). Canadian Journal of Psychiatry, 2017, 62, 543-550.	0.9	30
4	Antiepileptic use for epilepsy and nonepilepsy disorders. Neurology, 2016, 86, 939-946.	1.5	29
5	Treatment Strategies for Recurrent Clostridium difficile Infection. Canadian Journal of Hospital Pharmacy, 2013, 66, 361-8.	0.1	21
6	Prescription medication use during pregnancies that resulted in births and abortions (2001-2013): A retrospective population-based study in a Canadian population. PLoS ONE, 2019, 14, e0211319.	1.1	20
7	Opioid use during pregnancy: a population-based cohort study. CMAJ Open, 2017, 5, E517-E523.	1.1	17
8	Cerebrovascular, Cardiovascular, and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors. Journal of Clinical Psychopharmacology, 2017, 37, 332-340.	0.7	16
9	Translating Benzodiazepine Utilization Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting. Clinical Drug Investigation, 2018, 38, 565-572.	1.1	15
10	The 5-year pre- and post-hospitalization treated prevalence of mental disorders and psychotropic medication use in critically ill patients: a Canadian population-based study. Intensive Care Medicine, 2021, 47, 1450-1461.	3.9	15
11	Psychotropic Medication Use Before and During COVID-19: A Population-Wide Study. Frontiers in Pharmacology, 2022, 13, 886652.	1.6	15
12	Community Pharmacists' Perspectives on Dispensing Medications With the Potential for Misuse, Diversion, and Intentional Overdose: Results of a Province-Wide Survey of Community Pharmacists in Canada. Substance Use and Misuse, 2016, 51, 1724-1730.	0.7	14
13	Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a populationâ€based cohort study. Addiction, 2019, 114, 1791-1799.	1.7	14
14	Student perspectives of an online module for teaching physical assessment skills for dentistry, dental hygiene, and pharmacy students. Journal of Interprofessional Care, 2015, 29, 383-385.	0.8	13
15	A Physical Assessment Skills Module on Vital Signs. American Journal of Pharmaceutical Education, 2014, 78, 137.	0.7	11
16	Trends of COVID-19 incidence in Manitoba and public health measures: March 2020 to February 2022. BMC Research Notes, 2022, 15, 162.	0.6	11
17	Association of alcohol use disorder on alcoholâ€related cancers, diabetes, ischemic heart disease and death: a populationâ€based, matched cohort study. Addiction, 2022, 117, 368-381.	1.7	10
18	Psychotropic medication use before and after suicidal presentations to the emergency department: A longitudinal analysis. General Hospital Psychiatry, 2020, 63, 68-75.	1.2	9

#	Article	IF	CITATIONS
19	Use of pharmacotherapy for alcohol use disorder in Manitoba, Canada: A whole-population cohort study. PLoS ONE, 2021, 16, e0257025.	1.1	6
20	Risk of long-term benzodiazepine and Z-drug use following the first prescription among community-dwelling adults with anxiety/mood and sleep disorders: a retrospective cohort study. BMJ Open, 2021, 11, e046916.	0.8	5
21	Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study. Canadian Journal of Public Health, 2021, 112, 530-540.	1.1	4
22	Trends of Utilization of Antiseizure Medications Among Pregnant Women in Manitoba, Canada: A 20-Year Population-Based Study. Frontiers in Pharmacology, 2022, 13, 871136.	1.6	4
23	New antidepressant use in older adults: a Canadian population-based study (1997–2013). Aging and Mental Health, 2017, 21, 720-729.	1.5	3
24	Patient values and preferences on polypharmacy and deprescribing: a scoping review. International Journal of Clinical Pharmacy, 2021, 43, 1461-1499.	1.0	3
25	Health service use among Manitobans with alcohol use disorder: a population-based matched cohort study. CMAJ Open, 2020, 8, E762-E771.	1.1	2
26	Emerging Therapies for the Management of Multiple Sclerosis. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S2213.	0.4	1
27	Treating Recurrent Postmenopausal Vasomotor Symptoms in a Patient with a Positive Family History for Breast Cancer. The Consultant Pharmacist, 2015, 30, 38-44.	0.4	1
28	Validity of the days supply field in pharmacy administrative claims data for the identification of blister packaging of medications. Pharmacoepidemiology and Drug Safety, 2017, 26, 1540-1545.	0.9	1
29	Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. CMAJ Open, 2018, 6, E637-E642.	1.1	1
30	Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study. Drugs - Real World Outcomes, 2022, , .	0.7	1
31	Pharmacist medication reviews: Some hopeful comments about a negative finding. Journal of the American Pharmacists Association: JAPhA, 2017, 57, 298.	0.7	0
32	Pharmacist-led interventions for the management of medication misuse and abuse: A systematic review. Journal of the American Pharmacists Association: JAPhA, 2017, 57, 297-298.	0.7	0
33	Physical assessment in pharmacy practice: Perspectives from pharmacists, nonpharmacist health care providers and the public. Canadian Pharmacists Journal, 2021, 154, 193-204.	0.4	0
34	Insights into patient characteristics and documentation of the use of sedative-hypnotic/anxiolytics in primary care: a retrospective chart review study. , 2022, 23, 111.		0